Literature DB >> 2460543

Comparative immunogenicity of hepatitis B virus core and E antigens.

D R Milich1, A McLachlan, S Stahl, P Wingfield, G B Thornton, J L Hughes, J E Jones.   

Abstract

The nucleocapsid (hepatitis B core Ag (HBcAg] of the hepatitis B virus is a particulate Ag composed of a single polypeptide (p21). Although a non-particulate form of HBcAg designated hepatitis B e Ag (HBeAg) shares significant amino acid identity, the immune responses to these Ag appear to be regulated independently. This report describes the use of recombinant HBcAg and HBeAg to examine and compare murine T cell and B cell recognition of these related Ag. The HBcAg preparation was stable at pH 7.2 and 9.6 and expressed HBc antigenicity. However, the antigenicity of the HBeAg preparation was pH dependent. At pH 9.6 the HBeAg preparation was non-particulate and expressed HBe antigenicity exclusively; however, at pH 7.2 it was particulate and expressed both HBc and HBe antigenicities. Although this "hybrid" particle most likely does not exist naturally, it is a unique research reagent to investigate the interrelationship between HBcAg and HBeAg. HBcAg was significantly more immunogenic in terms of in vivo antibody production as compared to either the non-particulate or particulate forms of HBeAg. Nevertheless, in most murine strains HBcAg and HBeAg were equivalently immunogenic and crossreactive at the level of T cell activation. The disparity between anti-HBc and anti-HBe antibody production is best explained by the observation that HBcAg can function as a T cell-independent Ag whereas HBeAg is T cell dependent even when present within the same particulate structure as HBcAg. Furthermore, HBcAg was shown to function efficiently as an immunologic carrier moiety for the DNP hapten in athymic as well as euthymic mice in contrast to conventional carrier proteins. These results have implications relevant to the human immune responses to HBcAg and HBeAg during infection, and to vaccine development.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460543

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Diversity of core antigen epitopes of hepatitis B virus.

Authors:  D M Belnap; N R Watts; J F Conway; N Cheng; S J Stahl; P T Wingfield; A C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-03       Impact factor: 11.205

Review 2.  Membrane Ig-mediated triggering of B cell tolerance and B cell clonal expansion: implications for rheumatoid factor production in rheumatoid synovitis.

Authors:  P K Mongini; S M Rudich
Journal:  Springer Semin Immunopathol       Date:  1989

3.  Comparative antigenicity and immunogenicity of hepadnavirus core proteins.

Authors:  Jean-Noel Billaud; Darrell Peterson; Florian Schödel; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

Authors:  S L Tsai; P J Chen; M Y Lai; P M Yang; J L Sung; J H Huang; L H Hwang; T H Chang; D S Chen
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

6.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

7.  The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.

Authors:  D R Milich; F Schödel; J L Hughes; J E Jones; D L Peterson
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens.

Authors:  M Sällberg; K Townsend; M Chen; J O'Dea; T Banks; D J Jolly; S M Chang; W T Lee; D R Milich
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

9.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Authors:  C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 10.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.